Mirabegron Zentiva (Mirabegron)

Mirabegron selectively activates β3‑adrenergic receptors located in the detrusor muscle of the bladder. This activation relaxes the muscle during the storage phase, allowing the bladder to hold a larger volume of urine and reducing involuntary contractions that cause urgency and leakage.

The dosage of Mirabegron Zentiva is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function and concomitant medications. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for Mirabegron in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To request Mirabegron Zentiva, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative for overactive bladder is the antimuscarinic class (e.g., oxybutynin, tolterodine). Antimuscarinics block muscarinic receptors, often causing dry mouth and constipation, whereas Mirabegron works via β3‑adrenergic stimulation and has a different side‑effect profile, making it suitable for patients who cannot tolerate antimuscarinics.

Mirabegron Zentiva tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original packaging to protect from moisture and light, and ensure the container is tightly closed when not in use.

Mirabegron is taken orally as a tablet. Patients should swallow the tablet whole with water, and it may be taken with or without food. Consistency in timing each day helps maintain stable drug levels.

Serious adverse events include significant hypertension, urinary retention, angioedema, and rare cardiac events such as myocardial infarction. Patients should be monitored for sudden increases in blood pressure, difficulty urinating, or signs of an allergic reaction and seek medical attention promptly if they occur.

Mirabegron is contraindicated in patients with uncontrolled hypertension, severe hepatic impairment, or known hypersensitivity to the drug. Caution is also advised for individuals taking strong CYP2D6 inhibitors or those with conditions that could be worsened by increased blood pressure.